PERSEPHONE: Bonus Pod
May 19, 2018•13 min
Episode description
The release of ASCO's 2018 annual abstracts resulted in widespread media coverage of PERSEPHONE, the largest trial yet investigating 6 vs. 12 months of adjuvant trastuzumab in breast cancer. We get into the history of adjuvant trastuzumab studies and what to watch for going forward.
For the best experience, listen in Metacast app for iOS or Android
